Cheng Yongkang, Feng Sansan, Sheng Chuqiao, Yang Chunfeng, Li Yumei
Department of Pediatric Intensive Care Unit, The First Hospital of Jilin University, Changchun, Jilin, China.
Children's Hospital of The First Hospital of Jilin University, Changchun, Jilin, China.
Front Pharmacol. 2024 Feb 29;15:1354809. doi: 10.3389/fphar.2024.1354809. eCollection 2024.
Nobiletin (NOB) is a flavonoid derived from citrus peel that has potential as an alternative treatment for liver disease. Liver disease is a primary health concern globally, and there is an urgent need for effective drugs. This review summarizes the pharmacological characteristics of NOB and current and studies investigating the preventive and therapeutic effects of NOB on liver diseases and its potential mechanisms. The findings suggest that NOB has promising therapeutic potential in liver diseases. It improves liver function, reduces inflammation and oxidative stress, remodels gut microflora, ameliorates hepatocellular necrosis, steatosis, and insulin resistance, and modulates biorhythms. Nuclear factor erythroid 2-related factor 2 (Nrf2), nuclear transcription factor kappa (NF-κB), AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor α(PPAR-α), extracellular signal-regulated kinase (ERK), protein kinase B (AKT), toll-like receptor 4 (TLR4) and transcription factor EB (TFEB) signaling pathways are important molecular targets for NOB to ameliorate liver diseases. In conclusion, NOB may be a promising drug candidate for treating liver disease and can accelerate its application from the laboratory to the clinic. However, more high-quality clinical trials are required to validate its efficacy and identify its molecular mechanisms and targets.
诺米林(NOB)是一种从柑橘皮中提取的类黄酮,具有作为肝病替代治疗方法的潜力。肝病是全球主要的健康问题,迫切需要有效的药物。本综述总结了NOB的药理学特性,以及目前研究NOB对肝病的预防和治疗作用及其潜在机制的研究。研究结果表明,NOB在肝病治疗方面具有广阔的治疗潜力。它可改善肝功能,减轻炎症和氧化应激,重塑肠道微生物群,改善肝细胞坏死、脂肪变性和胰岛素抵抗,并调节生物节律。核因子红细胞2相关因子2(Nrf2)、核转录因子κB(NF-κB)、AMP激活蛋白激酶(AMPK)、过氧化物酶体增殖物激活受体α(PPAR-α)、细胞外信号调节激酶(ERK)、蛋白激酶B(AKT)、Toll样受体4(TLR4)和转录因子EB(TFEB)信号通路是NOB改善肝病的重要分子靶点。总之,NOB可能是一种有前途的治疗肝病的候选药物,并可加速其从实验室到临床的应用。然而,需要更多高质量的临床试验来验证其疗效,并确定其分子机制和靶点。